solutions 
Fierce Pharma
MARCH 19, 2024
New York's IFF—which dabbles in food, beverage, beauty and pharmaceutical supply chains, among others—has agreed to sell its pharma solutions business to French plant-based ingredient maker Roquette for up to $2.85 After a two-year stint under Merck & Co.
MedCity News
APRIL 4, 2024
Employers are struggling with point solution fatigue, but does that mean new startups shouldn’t be selling to them anymore? The post Should New Entrants Bother With Selling Point Solutions To Employers? Experts have mixed opinions. appeared first on MedCity News.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
OCTOBER 25, 2023
Cami Stewart-Myers of PPD FSP Solutions introduces us to the concept of implementation leads and how they help to smooth out the delivery of FSP partnerships – chiefly by identifying and then coordinating solutions to bottlenecks.
MedCity News
OCTOBER 26, 2023
It’s difficult for employers to work with multiple point solutions that target very specific populations, investors said during a panel discussion. Instead, many investors are more interested in platform-based solutions that support more people.
Advertisement
Demand-led supply and direct-to-patient distribution are next-generation solutions that are helping to meet these growing needs, allowing for more streamlined processes and patient-centric studies.
Fierce Pharma
JANUARY 13, 2023
AmerisourceBergen Expands Global Footprint and Commercialization Solutions with Acquisition of PharmaLex. Fri, 01/13/2023 - 10:18.
MedCity News
APRIL 19, 2024
The post How Are You Guiding Employers on Virtual Care Solutions Within Their Benefits Plan? Attenton, healthcare benefit consultants: Take part in our survey and share some of the trends you are seeing among your clients. A full report of the findings will be available later this year. appeared first on MedCity News.
Advertiser: ZoomInfo
Those implementing a B2B sales and marketing intelligence solution reported that they have realized 35% more leads in their pipeline and 45% higher-quality leads leading to higher revenue and growth. More organizations are investing in B2B sales and marketing intelligence solutions. Forrester found “only 1.2%
Advertiser: ZoomInfo
In this eBook, we’ll run through real-world examples that show how RevOps teams can benefit from modern solutions for the access, management, and activation of their GTM data.
Advertiser: ZoomInfo
Solution-centric mentality. Read on to learn how to adopt specific workflows and approaches that append your existing processes to deliver value to your prospects and internal counterparts. What's covered: Targeted prospecting. Efficient outreach strategy.
Advertiser: ZoomInfo
The digital age has brought about increased investment in data quality solutions. 64% of successful data-driven marketers say improving data quality is the most challenging obstacle to achieving success. Businesses are realizing that it isn’t just about the volume of data they have available; it’s about the accuracy of information.
Advertiser: ZoomInfo
Marketers are uniquely positioned to provide creative solutions to aid their organization in times of change and chart a course for navigating success. When the dust settles, we have a responsibility to turn our shock and grief into fierce determination and lead the charge of responsible, strategic, and sustainable future growth.
Advertiser: ZoomInfo
As organizations chase new revenue targets, B2B sales leaders must examine cutting edge prospecting solutions that proactively help reps identify, connect with, and close qualified buyers faster. Steps your buying committee must go through when purchasing a prospecting solution.
Advertisement
In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinical trials.
Expert insights. Personalized for you.
261 
Let's personalize your content